Adrenocortical carcinoma natural history: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 14: | Line 14: | ||
==Prognosis== | ==Prognosis== | ||
Adrenocortical carcinoma, generally, carries a poor prognosis.<ref name=allolio>{{cite journal | author = Allolio B, Fassnacht M | title = Clinical review: Adrenocortical carcinoma: clinical update. | journal = J Clin Endocrinol Metab | volume = 91 | issue = 6 | pages = 2027-37 | year = 2006 | id = PMID 16551738}} [http://jcem.endojournals.org/cgi/content/full/91/6/2027 Free Full Text].</ref> | Adrenocortical carcinoma, generally, carries a poor prognosis.<ref name="allolio">{{cite journal | author = Allolio B, Fassnacht M | title = Clinical review: Adrenocortical carcinoma: clinical update. | journal = J Clin Endocrinol Metab | volume = 91 | issue = 6 | pages = 2027-37 | year = 2006 | id = PMID 16551738}} [http://jcem.endojournals.org/cgi/content/full/91/6/2027 Free Full Text].</ref> | ||
The five-year disease-free survival rate for a complete resection of a [[Cancer staging|stage]] I-III is approximately 30%.<ref name=allolio/> | The five-year disease-free survival rate for a complete resection of a [[Cancer staging|stage]] I-III is approximately 30%.<ref name="allolio" /> | ||
The most important prognostic factors are: | The most important prognostic factors are: | ||
| Line 25: | Line 25: | ||
* Diameter more than 6.5 cm | * Diameter more than 6.5 cm | ||
* Ki-67/MIB1 labeling index (antigen identified by monoclonal antibody Ki-67) | * Ki-67/MIB1 labeling index (antigen identified by monoclonal antibody Ki-67) | ||
* Survival ranges from a few months to several years. (242) | |||
* In the Michigan Endocrine Oncology Repository, roughly 5% of all patients diagnosed with ACC will have a disease course of _10 years (T.E., unpublished results). Although this may be caused by a referral bias, there is an emerging notion of an ACC population with exceptionally long survival. Despite these variations in survival, prognostic factors have not been definitively researched. Naturally, age at diagnosis is correlated with decreased overall survival (243). However, whether this is true for tumor-free survival remains unclear. Tumor characteristics of malignancy and velocity of tumor growth are usually related to a decreased survival. Tumor extent (eg, stage), specifically the presence of distant metastasis and number of organs involved in metastatic disease, confers a worse prognosis (243, 244). High tumor grade (_20 mitoses per HPF) is also an unfavorable prognostic indicator (245). Although older studies did not show any differences in prognoses for patients harboring different hormone secretion subtypes of ACC, some recent studies identified cortisol production as an adverse prognostic factor (12, 85, 244). | |||
==References== | ==References== | ||
Revision as of 18:56, 21 September 2017
|
Adrenocortical carcinoma Microchapters |
|
Differentiating Adrenocortical carcinoma from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Study |
|
Adrenocortical carcinoma natural history On the Web |
|
American Roentgen Ray Society Images of Adrenocortical carcinoma natural history |
|
Risk calculators and risk factors for Adrenocortical carcinoma natural history |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Raviteja Guddeti, M.B.B.S. [2] Ahmad Al Maradni, M.D. [3]
Overview
Prognosis is generally poor, and the 5-year survival rate of patients with adrenocortical carcinoma stage I-III is approximately 30%. Complication may include metastasis, Conn syndrom and Cushing syndrom
Complications
The following are the complications of Adrenocortical carcinoma:
- Cushing's syndrome
- Conn syndrome
- Hypertension
- Local and distant metastasis
- Paraneoplastic syndrome
- Tumor thrombus formation
Prognosis
Adrenocortical carcinoma, generally, carries a poor prognosis.[1] The five-year disease-free survival rate for a complete resection of a stage I-III is approximately 30%.[1]
The most important prognostic factors are:
- Age of the patient
- Stage of the tumor
- Mitotic activity
- Venous invasion
- Weight more than 50 Kg
- Diameter more than 6.5 cm
- Ki-67/MIB1 labeling index (antigen identified by monoclonal antibody Ki-67)
- Survival ranges from a few months to several years. (242)
- In the Michigan Endocrine Oncology Repository, roughly 5% of all patients diagnosed with ACC will have a disease course of _10 years (T.E., unpublished results). Although this may be caused by a referral bias, there is an emerging notion of an ACC population with exceptionally long survival. Despite these variations in survival, prognostic factors have not been definitively researched. Naturally, age at diagnosis is correlated with decreased overall survival (243). However, whether this is true for tumor-free survival remains unclear. Tumor characteristics of malignancy and velocity of tumor growth are usually related to a decreased survival. Tumor extent (eg, stage), specifically the presence of distant metastasis and number of organs involved in metastatic disease, confers a worse prognosis (243, 244). High tumor grade (_20 mitoses per HPF) is also an unfavorable prognostic indicator (245). Although older studies did not show any differences in prognoses for patients harboring different hormone secretion subtypes of ACC, some recent studies identified cortisol production as an adverse prognostic factor (12, 85, 244).
References
- ↑ 1.0 1.1 Allolio B, Fassnacht M (2006). "Clinical review: Adrenocortical carcinoma: clinical update". J Clin Endocrinol Metab. 91 (6): 2027–37. PMID 16551738. Free Full Text.